Sonography of gallbladder abnormalities in acromegaly patients following octreotide and ursodiol therapy: Incidence and time course

Journal of Clinical Ultrasound

Volumn 26, Issue 6, 1998, Pages 289-294

  Avila, Nilo A ^a   Shawker, Thomas H ^a   Roach, Paris ^b   Bradford, Mary H ^a   Skarulis, Monica C ^c   Eastman, Richard ^c  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

Acromegaly; Gallbladder; Octreotide; Ultrasonography; Ursodiol

Indexed keywords

GROWTH HORMONE; OCTREOTIDE; SOMATOMEDIN C; URSODEOXYCHOLIC ACID;

ACROMEGALY; ADULT; ARTICLE; CHOLELITHIASIS; CLINICAL ARTICLE; DRUG EFFECT; ECHOGRAPHY; FEMALE; GALLBLADDER DISEASE; HUMAN; INCIDENCE; MALE; SUBCUTANEOUS DRUG ADMINISTRATION;

ACROMEGALY; ADULT; CHOLAGOGUES AND CHOLERETICS; FEMALE; GALLBLADDER; GALLBLADDER DISEASES; HORMONES; HUMANS; MALE; MIDDLE AGED; OCTREOTIDE; TIME FACTORS; URSODEOXYCHOLIC ACID;

EID: 0031776038     PISSN: 00912751     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0096(199807/08)26:6<289::AID-JCU2>3.0.CO;2-E     Document Type: Article

References (13)

1. Eastman RC, Gorden P, Glatstein E, et al: Radiation therapy of acromegaly. Endocrinol Metab Clin North Am 1992;21:693.
2. Shi Y-F, Zhu X-F, Harris AG, et al: Prospective study of the long-term effects of somatostatin analog (octreotide) on gallbladder function and gallstone formation in Chinese acromegalic patients. J Clin Endocrinol Metab 1993;76:32.
3. Lamberts SWJ, Uitterlinden P, Vrschoor L, et al: Long-term treatment of acromegaly with the somatostain analogue SMS 201-995. N Engl J Med 1985;313:1576.
4. Barkan AL, Kelch RP, Hopwood NJ, et al: Treatment of acromegaly with the long acting somatostatin analogue SMS 201-995. J Clin Endocrinol Metab 1988;66:16.
5. Sassolas G, Harris AG, James-Deidier A: The French SMS 201-995 Acromegaly Study Group. Long term effect of incremental doses of the somatostatin analog SMS 201-995 in 58 acromegalic patients. J Clin Endocrinol Metab 1977;71:391.
6. Barkan AL, Lloyd RV, Chandler WF, et al: Preoperative treatment of acromegaly with long-acting somatostatin analog SMS 201-995: shrinkage of invasive pituitary microadenomas and improved surgical remission rate. J Clin Endocrinol Metab 1988;67:1040.
7. Ho KY, Weissberger AJ, Marbach P, et al: Therapeutic efficacy of the somatostatin analogue SMS 201-005 (octreotide) in acromegaly. Ann Intern Med 1990;112:173.
8. Eastman RC, Arakaki RF, Shawker TS, et al: A prospective examination of octreotide-induced gallbladder changes in acromegaly. Clin Endocrinol (Oxf) 1992;36:265.
9. Hussaini SH, Pereira SP, Murphy GM, et al: Composition of gallbladder stones associated with octreotide: response to oral ursodeoxycholic acid. Gut 1995;36:126.
10. Everson GT, Braverman DZ, Johnson ML, et al: A critical evaluation of real time ultrasonography for the study of gallbladder volume and contraction. Gastroenterology 1980;79:40.
11. Dodds WJ, Groh WJ, Darweesh RM, et al: Sonographic measurement of gallbladder volume. AJR Am J Roentgenol 1985;145:1009.
12. Van Liessum PA, Hopman WPM, Pieters FGGM, et al: Postprandial gallbladder motility during long term treatment with the long-acting somatostatin analog SMS 201-995 in acromegaly. J Clin Endocrinol Metab 1989;69:557.
13. Zhu XF, Shi YF, Dai Q, et al: Effect of small doses of a somatostatin analogue, octreotide, on gallbladder contractility in normal Chinese adults. Dig Dis Sci 1992;37:105.